Eshan U Patel1, Sunil S Solomon2, Gregory M Lucas3, Allison M McFall1, Cecília Tomori4, Aylur K Srikrishnan5, Muniratnam S Kumar5, Oliver Laeyendecker6, David D Celentano7, David L Thomas3, Thomas C Quinn6, Shruti H Mehta8. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; YR Gaitonde Centre for AIDS Research and Education, Chennai, India. 3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Johns Hopkins University School of Nursing, Baltimore, MD, USA; Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. YR Gaitonde Centre for AIDS Research and Education, Chennai, India. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Baltimore MD, USA. 7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 8. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: smehta@jhu.edu.
Abstract
BACKGROUND: Although drug use stigma is globally pervasive, quantitative evidence of its role in hepatitis C virus (HCV) transmission is limited. We evaluated the psychometric properties of a drug use stigma scale and examined the association between drug use stigma and active HCV infection among a community-based sample of people who inject drugs (PWID) in India. METHODS: Between 8/2016 and 5/2017, a cross-sectional sample of PWID was recruited from 12 Indian cities (~1000/city) using respondent-driven sampling. Participants were ≥18 years old and reported injection drug use (IDU) in the past 2 years. Multivariable logistic regression with a random-intercept for each city was used to estimate adjusted odds ratios (aOR) of active HCV infection (RNA>30 IU/mL). Analyses incorporated RDS-II weights. RESULTS: Of 11,663 participants, 73.1% reported IDU in the past 6 months and 33.8% had active HCV infection. Exploratory factor analysis yielded a four-factor solution of enacted, vicarious, felt normative and internalized drug use stigma with high internal consistency (Cronbach's α: 0.85-0.92). In analyses adjusted for age, gender, northeast region, education, homelessness, incarceration, alcohol dependence, HIV status, frequency of IDU, and ever sharing needles/syringes, PWID reporting any enacted stigma had greater odds of active HCV infection (aOR = 1.27 [95% CI = 1.13-1.43]) as did PWID with internalized stigma scores in the highest quartile (vs. lowest quartile; aOR = 1.69 [95% CI = 1.11-2.56]). Among PWID who reported IDU in the past 6 months, multiple forms of stigma were associated with higher frequency of IDU, sharing needles/syringes, having multiple injection partners, and IDU in public spaces. CONCLUSION: Using a multidimensional drug use stigma scale, various forms of stigma were significantly associated with active HCV infection and injection drug use-related risk behaviors. Collectively, these data suggest that drug use stigma may play a role in HCV transmission and impede efforts to achieve HCV elimination. Strategies to diminish drug use stigma are warranted.
BACKGROUND: Although drug use stigma is globally pervasive, quantitative evidence of its role in hepatitis C virus (HCV) transmission is limited. We evaluated the psychometric properties of a drug use stigma scale and examined the association between drug use stigma and active HCV infection among a community-based sample of people who inject drugs (PWID) in India. METHODS: Between 8/2016 and 5/2017, a cross-sectional sample of PWID was recruited from 12 Indian cities (~1000/city) using respondent-driven sampling. Participants were ≥18 years old and reported injection drug use (IDU) in the past 2 years. Multivariable logistic regression with a random-intercept for each city was used to estimate adjusted odds ratios (aOR) of active HCV infection (RNA>30 IU/mL). Analyses incorporated RDS-II weights. RESULTS: Of 11,663 participants, 73.1% reported IDU in the past 6 months and 33.8% had active HCV infection. Exploratory factor analysis yielded a four-factor solution of enacted, vicarious, felt normative and internalized drug use stigma with high internal consistency (Cronbach's α: 0.85-0.92). In analyses adjusted for age, gender, northeast region, education, homelessness, incarceration, alcohol dependence, HIV status, frequency of IDU, and ever sharing needles/syringes, PWID reporting any enacted stigma had greater odds of active HCV infection (aOR = 1.27 [95% CI = 1.13-1.43]) as did PWID with internalized stigma scores in the highest quartile (vs. lowest quartile; aOR = 1.69 [95% CI = 1.11-2.56]). Among PWID who reported IDU in the past 6 months, multiple forms of stigma were associated with higher frequency of IDU, sharing needles/syringes, having multiple injection partners, and IDU in public spaces. CONCLUSION: Using a multidimensional drug use stigma scale, various forms of stigma were significantly associated with active HCV infection and injection drug use-related risk behaviors. Collectively, these data suggest that drug use stigma may play a role in HCV transmission and impede efforts to achieve HCV elimination. Strategies to diminish drug use stigma are warranted.
Authors: Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi Journal: Drug Alcohol Depend Date: 2019-03-08 Impact factor: 4.492
Authors: Carl Latkin; Aylur K Srikrishnan; Cui Yang; Sethulakshmi Johnson; Sunil S Solomon; Suresh Kumar; David D Celentano; Suniti Solomon Journal: Drug Alcohol Depend Date: 2010-05-13 Impact factor: 4.492
Authors: Wayne T Steward; Gregory M Herek; Jayashree Ramakrishna; Shalini Bharat; Sara Chandy; Judith Wrubel; Maria L Ekstrand Journal: Soc Sci Med Date: 2008-07-01 Impact factor: 4.634
Authors: Sunil S Solomon; Gregory M Lucas; David D Celentano; Allison M McFall; Elizabeth Ogburn; Lawrence H Moulton; Aylur K Srikrishnan; M Suresh Kumar; Santhanam Anand; Suniti Solomon; Shruti H Mehta Journal: BMC Health Serv Res Date: 2016-11-14 Impact factor: 2.655
Authors: Janet M Turan; Melissa A Elafros; Carmen H Logie; Swagata Banik; Bulent Turan; Kaylee B Crockett; Bernice Pescosolido; Sarah M Murray Journal: BMC Med Date: 2019-02-15 Impact factor: 8.775
Authors: Kirsten M A Trayner; Andrew McAuley; Norah E Palmateer; David J Goldberg; Samantha J Shepherd; Rory N Gunson; Emily J Tweed; Saket Priyadarshi; Catriona Milosevic; Sharon J Hutchinson Journal: Int J Drug Policy Date: 2020-01-22
Authors: Eshan U Patel; Sunil S Solomon; Allison M McFall; Neia Prata Menezes; Cecília Tomori; Aylur K Srikrishnan; Muniratnam S Kumar; David D Celentano; Gregory M Lucas; Shruti H Mehta Journal: AIDS Date: 2022-06-22 Impact factor: 4.632